TRANSGENOMIC INC Form DEFA14A October 19, 2016

## **UNITED STATES**

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## **SCHEDULE 14A INFORMATION**

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant x Filed by a party other than the Registrant "

Check the appropriate box:

oPreliminary Proxy Statement o**Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))** oDefinitive Proxy Statement xDefinitive Additional Materials oSoliciting Material under Rule 14a-12

### Transgenomic, Inc.

(Name of Registrant as Specified in Its Charter)

Payment of Filing Fee (Check the appropriate box):

- x No fee required.
- " Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

# Edgar Filing: TRANSGENOMIC INC - Form DEFA14A

- (1) Title of each class of securities to which transaction applies:
- (2) Aggregate number of securities to which transaction applies:
- (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
- (4) Proposed maximum aggregate value of transaction:
- (5) Total fee paid:
- " Fee paid previously with preliminary materials:

" Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

- (1) Amount previously paid:
- (2) Form, Schedule or Registration Statement No.:
- (3) Filing Party:
- (4) Date Filed:

## **EXPLANATORY NOTE**

This proxy statement supplement, dated October 19, 2016, supplements the definitive proxy statement (the "Proxy Statement") of Transgenomic, Inc. (the "Company"), filed with the Securities and Exchange Commission on September 22, 2016, relating to the Special Meeting of Stockholders of the Company originally held at the offices of Paul Hastings LLP, 4747 Executive Drive, 12<sup>th</sup> Floor, San Diego, California 92121, on October 11, 2016, which meeting was adjourned until Monday, October 31, 2016 at 10:00 a.m. Pacific Time.

The purpose of this proxy statement supplement is to correct an error related to the vote required to approve the authorization of the Company's Board of Directors to, in its discretion, amend the Company's Third Amended and Restated Certificate of Incorporation (the "Proposal"), as disclosed on pages 5 and 17 of the Proxy Statement. Set forth below are the applicable sections on pages 5 and 17, respectively, of the Proxy Statement with the corrected vote required to approve the Proposal. Except as specifically supplemented by the information contained herein, all information set forth in the Proxy Statement remains unchanged.

Page 5

### **Vote Required**

On the Record Date, there were 23,744,898 issued and outstanding shares of our common stock and 214,705 issued and outstanding shares of Series A-1 Preferred Stock. Each share of common stock is entitled to one vote on each matter to be voted on at the Special Meeting. The holders of Series A-1 Preferred Stock are entitled to 0.93 votes for every one share of Series A-1 Preferred Stock held on each matter to be voted on at the Special Meeting. Accordingly, the owners of Series A-1 Preferred Stock have an aggregate of 199,675 votes with respect to each matter to be voted on at the Special Meeting. The holders of Series A-1 Preferred Stock will vote together as a single class with the holders of common stock on Proposal One.

Proposal One: Authorization of the Board to, in its discretion, amend our Third Amended and Restated Certificate of Incorporation to effect a reverse stock split of our common stock at a ratio of between one-for-ten to one-for-thirty, such ratio to be determined by the Board. The affirmative vote of a majority of the shares of our common stock and Series A-1 Preferred Stock outstanding and entitled to vote on the matter, voting together as a single class (with each one share of Series A-1 Preferred Stock being entitled to 0.93 votes), is required to approve the authorization of the Board to, in its discretion, amend our Third Amended and Restated Certificate of Incorporation to

# Edgar Filing: TRANSGENOMIC INC - Form DEFA14A

effect a reverse stock split of our common stock at a ratio of between one-for-ten to one-for-thirty, such ratio to be determined by the Board. Abstentions and broker non-votes will be counted as votes against this proposal.

Page 17

# **Vote Required**

The affirmative vote of a majority of the shares of our common stock and Series A-1 Preferred Stock outstanding and entitled to vote on the matter, voting together as a single class (with each one share of Series A-1 Preferred Stock being entitled to 0.93 votes), is required to approve the authorization of the Board to, in its discretion, amend our Third Amended and Restated Certificate of Incorporation to effect a reverse stock split of our common stock at a ratio of between one-for-ten to one-for-thirty, such ratio to be determined by the Board.